Fact CheckerSign in

NCT07591376Completed

A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers

Source: ClinicalTrials.gov · Last updated 15 May 2026

Brief summary (registry, in English)

Physical activity prior to and during chemo- and/or immunotherapy for lung cancer appears important. This may also be true for patients with lung cancer treated with radiation therapy. However, adherence to an exercise program sometimes may be challenging for the patients, particularly if they experience fatigue or other adverse events. The question arose whether an easy-to-use mobile app installed on the patient's smart phone reminding patients several times daily to perform a certain number of steps will have a positive effect on their physical activity during a course of radiation therapy. Such an app has been developed within the Interreg project HeAT (Health Advancing Technologies for Elderly). However, before this app can be tested in a prospective trial involving patients, its usability should to be evaluated by healthy volunteers. In the present prospective study, 30 healthy volunteers test and rate ten aspects related to the usability of the app. The healthy volunteers have to download a reminder app, which has been designed by the Lübeck based company Nextlabel Offene Handelsgesellschaft (OHG). After receiving the link for the download of the app from Nextlabel OHG by e-mail, the participants are asked to test the app and complete a questionnaire. They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the reminder app. The satisfaction rate represents the rate of participants who affirmed a statement. If this rate was \<60%, the reminder app was rated as not being useful. If the rate was between ≥60% but \<80%, the app was regarded useful but required further optimization regarding the corresponding section. In addition, iPhone and Android users are compared with respect to the satisfaction rates.

Status (registry)
Completed
Study type
Interventional
Enrollment
30 (actual)
First submitted
5 May 2026
Start date
19 Mar 2026
Primary completion date
21 Apr 2026
Lead sponsor
University Hospital Schleswig-Holstein
Diseases
Lung cancer
NCT number
NCT07591376

What you commit to

  • Study type: Interventional
  • Participants enrolled: 30
  • From 19 Mar 2026 to the primary completion date, 21 Apr 2026
  • 2 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • 1\. Expected non-compliance

Who the study is looking for

  • Possession of and ability to use a smart phone plus a step counter
  • Age ≥18 years
  • Written informed consent
  • Capacity of the participant to consent

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Radiation Oncology, University of Luebeck
Coordinator of this site? Confirm its status
LübeckGermanyUnknown status
Department of Oncology Vejle Hospital, University Hospital of Southern Denmark
Coordinator of this site? Confirm its status
VejleDenmarkUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.